BOLD Stock Analysis: Buy, Sell, or Hold?
BOLD - Boundless Bio, Inc. Common Stock
$1.42
-0.07 (-4.70%)
▼
5d:
-8.39%
30d:
-10.13%
90d:
+23.48%
HOLD
LOW Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 08, 2026
0d
Get Alerted When BOLD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BOLD shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: BOLD shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: BOLD is currently trading at $1.42, which is considered slightly low relative to its 30-day fair value range of $1.36 to $1.62.
Technical Outlook: Technically, BOLD is in a uptrend. The price is currently testing key support at $1.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+168.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BOLD is in a uptrend. The price is currently testing key support at $1.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+168.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.36 -
$1.62
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.7%)
- BULLISH: Trading 168.5% below Wall St target ($4.00)
- CAUTION: Recommendation downgraded due to -8.4% 5-day decline
Trading Range Analysis
30-Day Trading Range
$1.36 -
$1.62
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.40
Resistance Level
$1.65
Current Trend
Uptrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.16
Wall Street Target
$4.00
(+168.5%)
Share & Embed Analysis
Last updated: May 18, 2026 4:57 PM ET
Data refreshes hourly during market hours. Next update: 5:57 PM
Data refreshes hourly during market hours. Next update: 5:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BOLD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 56 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 51 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 56 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$203 | 53 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 58 HOLD |
